Please login to the form below

Not currently logged in
Email:
Password:

Abilify Maintena

This page shows the latest Abilify Maintena news and features for those working in and with pharma, biotech and healthcare.

Indivior push to diversify boosted by schizophrenia drug approval

Indivior push to diversify boosted by schizophrenia drug approval

Indivior push to diversify boosted by schizophrenia drug approval. Perseris will face competition from Lundbeck/Otsuka’s Abilify Maintena and J&J’s Invega Sustenna. ... It will launch in competition to other monthly therapies, such as

Latest news

  • Abilify Maintena launches in Europe Abilify Maintena launches in Europe

    Abilify Maintena launches in Europe. Schizophrenia treatment is a key product to help Lundbeck replace lost Cipralex sales. ... Lundbeck said today that Abilify Maintena will be on the market in 10 countries by the end of year.

  • Otsuka/Lundbeck say brexpiprazole works in phase III trial Otsuka/Lundbeck say brexpiprazole works in phase III trial

    Approval would reinforce Lundbeck and Otsuka's central nervous system franchise, which was also boosted last year by the approval of a once-monthly formulation of aripiprazole - Abilify Maintena - which is ... Lundbeck and Otsuka renewed their CNS

  • Ipragliflozin beats diabetes rivals to Japanese approval Ipragliflozin beats diabetes rivals to Japanese approval

    2010. - Otsuka Pharmaceutical has filed for approval of its once-monthly intramuscular formulation of antipsychotic Abilify (aripiprazole) as a maintenance treatment for schizophrenia. ... The product was launched in the US last year under the Abilify

  • Profits down at Lundbeck as revenues slip Profits down at Lundbeck as revenues slip

    and depot antipsychotic Abilify Maintena (aripiprazole). ... Lundbeck said uptake of Abilify Maintena is "encouraging", although it did not break out sales figure for the drug, which reached the US market in March 2013 and has been recommended

  • EMA backs drugs from Novo, Otsuka, AZ, Janssen, GSK EMA backs drugs from Novo, Otsuka, AZ, Janssen, GSK

    Otsuka also received good news, winning CHMP backing for schizophrenia treatment Abilify Maintena (aripiprazole). ... The medicine is an extended release injectable version of Abilify, which is marketed by Otsuka as part of a collaboration with Lundbeck.

More from news
Approximately 2 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Pharma deals during March 2013 Pharma deals during March 2013

    At the end of February, the FDA approved Abilify Maintena (aripiprazole), an intramuscular extended-release depot formulation for the treatment of schizophrenia and the first commercialised product to evolve from this ... injectable in 14 European

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...

Infographics